NO20004363L - Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism - Google Patents
Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autismInfo
- Publication number
- NO20004363L NO20004363L NO20004363A NO20004363A NO20004363L NO 20004363 L NO20004363 L NO 20004363L NO 20004363 A NO20004363 A NO 20004363A NO 20004363 A NO20004363 A NO 20004363A NO 20004363 L NO20004363 L NO 20004363L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- autism
- obsessive
- antagonists
- treatment
- Prior art date
Links
- 206010003805 Autism Diseases 0.000 title abstract 2
- 208000020706 Autistic disease Diseases 0.000 title abstract 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 title abstract 2
- 208000030990 Impulse-control disease Diseases 0.000 title abstract 2
- 208000027520 Somatoform disease Diseases 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 208000018459 dissociative disease Diseases 0.000 title abstract 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Fremgangsmåte for å behandle tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, spiseforstyrrelser, impulskontrollforstyrrelser og autisme er beskrevet. Disse forstyrrelser behandles ved å administrere en effektiv mengde av en Dl-/D5-antagonist.Procedures for treating compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders and autism are described. These disorders are treated by administering an effective amount of a D1 / D5 antagonist.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3320598A | 1998-03-02 | 1998-03-02 | |
| PCT/US1999/003721 WO1999044615A1 (en) | 1998-03-02 | 1999-03-01 | Use of d1/d5 antagonists for treating obsessive compulsive disorders, somatoform disorders, dissociative, eating disorders, impulse control disorders and autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20004363D0 NO20004363D0 (en) | 2000-09-01 |
| NO20004363L true NO20004363L (en) | 2000-10-31 |
Family
ID=21869083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20004363A NO20004363L (en) | 1998-03-02 | 2000-09-01 | Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1058551A1 (en) |
| JP (1) | JP2002505291A (en) |
| KR (1) | KR20010041477A (en) |
| CN (1) | CN1291893A (en) |
| AR (1) | AR018297A1 (en) |
| AU (1) | AU2778099A (en) |
| BR (1) | BR9908392A (en) |
| CA (1) | CA2322201A1 (en) |
| CO (1) | CO4910136A1 (en) |
| HU (1) | HUP0101057A3 (en) |
| IL (1) | IL137715A0 (en) |
| NO (1) | NO20004363L (en) |
| PE (1) | PE20000333A1 (en) |
| SK (1) | SK12962000A3 (en) |
| WO (1) | WO1999044615A1 (en) |
| ZA (1) | ZA991638B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410527B1 (en) * | 1998-03-02 | 2002-06-25 | Schering Corporation | Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism |
| RU2374245C1 (en) | 2008-08-22 | 2009-11-27 | Андрей Александрович Иващенко | Ligand with wide range of simultaneous receptor activity, pharmaceutical composition, method of preparing said composition and medicinal agent |
| HRP20251123T1 (en) * | 2012-07-12 | 2025-11-21 | Emalex Biosciences, Inc. | EKOPIPAM FOR THE TREATMENT OF TOURETTE'S SYNDROME |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| BR9814830A (en) * | 1997-10-28 | 2000-10-03 | Schering Corp | Desire reduction method in mammals |
-
1999
- 1999-03-01 EP EP99908318A patent/EP1058551A1/en not_active Withdrawn
- 1999-03-01 IL IL13771599A patent/IL137715A0/en unknown
- 1999-03-01 CN CN99803496A patent/CN1291893A/en active Pending
- 1999-03-01 CA CA002322201A patent/CA2322201A1/en not_active Abandoned
- 1999-03-01 SK SK1296-2000A patent/SK12962000A3/en unknown
- 1999-03-01 KR KR1020007009634A patent/KR20010041477A/en not_active Withdrawn
- 1999-03-01 ZA ZA9901638A patent/ZA991638B/en unknown
- 1999-03-01 BR BR9908392-2A patent/BR9908392A/en not_active IP Right Cessation
- 1999-03-01 JP JP2000534217A patent/JP2002505291A/en not_active Withdrawn
- 1999-03-01 CO CO99012525A patent/CO4910136A1/en unknown
- 1999-03-01 PE PE1999000169A patent/PE20000333A1/en not_active Application Discontinuation
- 1999-03-01 WO PCT/US1999/003721 patent/WO1999044615A1/en not_active Ceased
- 1999-03-01 AR ARP990100860A patent/AR018297A1/en unknown
- 1999-03-01 HU HU0101057A patent/HUP0101057A3/en unknown
- 1999-03-01 AU AU27780/99A patent/AU2778099A/en not_active Abandoned
-
2000
- 2000-09-01 NO NO20004363A patent/NO20004363L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK12962000A3 (en) | 2001-08-06 |
| AU2778099A (en) | 1999-09-20 |
| CO4910136A1 (en) | 2000-04-24 |
| HUP0101057A2 (en) | 2001-08-28 |
| AR018297A1 (en) | 2001-11-14 |
| JP2002505291A (en) | 2002-02-19 |
| WO1999044615A1 (en) | 1999-09-10 |
| IL137715A0 (en) | 2001-10-31 |
| CN1291893A (en) | 2001-04-18 |
| HUP0101057A3 (en) | 2001-09-28 |
| EP1058551A1 (en) | 2000-12-13 |
| CA2322201A1 (en) | 1999-09-10 |
| BR9908392A (en) | 2000-10-31 |
| ZA991638B (en) | 1999-09-01 |
| NO20004363D0 (en) | 2000-09-01 |
| PE20000333A1 (en) | 2000-05-13 |
| KR20010041477A (en) | 2001-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE515513T1 (en) | TREATMENT OF FIBROSIS BY ANTAGONISM BETWEEN IL-13 AND IL-13 RECEPTOR CHAINS | |
| DE60133029D1 (en) | MEANS FOR THE PREVENTION OR TREATMENT OF PSORIASI | |
| DE60035232D1 (en) | (S, S) -Reboxetine for the treatment of chronic fatigue syndrome | |
| MY151032A (en) | Treatment of tnf? related disorders | |
| ATE526959T1 (en) | TREATMENT OF MUSCLE WASTING WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS | |
| AP2004003026A0 (en) | Methods for treating ocular neovascular diseases. | |
| ATE555803T1 (en) | USE OF OSTEOPONTIN TO TREAT AND/OR PREVENT NEUROLOGICAL DISEASES | |
| GB2368796A (en) | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies | |
| ATE263563T1 (en) | REMEDIES FOR ITCHING | |
| NO20013641L (en) | BAFF, related blocking agents and their use in stimulating and inhibiting B cells and immunoglobulins in immune responses | |
| MXPA03007960A (en) | Compounds and methods for the treatment of urogenital disorders. | |
| IL148071A0 (en) | Method for treatment of symptoms of central nervous system disorders | |
| EP0895781A3 (en) | Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins | |
| PL346876A1 (en) | Mglur5 antagonists for the treatment of pain and anxiety | |
| EA200400235A1 (en) | COMBINED THERAPY FOR CANCER TREATMENT | |
| MXPA04007391A (en) | Fused tricyclic heterocycles useful for treating hyper-proliferative disorders. | |
| EP1465968A4 (en) | Methods for treating deodorizer distillate | |
| SI1608685T1 (en) | Vegf antagonists for the treatment of diabetes | |
| TR200101149T2 (en) | Treatment of external retinal disorders. | |
| MXPA03010406A (en) | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg. | |
| MXPA03011270A (en) | Use of rank antagonists to treat cancer. | |
| EP1419236A4 (en) | Methods for treating or preventing sclerotic disorders using cd2-binding agents | |
| WO2002061430A3 (en) | Methods and reagents for treating autoimmune disorders | |
| ATE345818T1 (en) | S-METHYL-DIHYDRO-ZIPRASIDONE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS. | |
| NO20004363D0 (en) | Use of D1 / D5 antagonists for the treatment of obsessive-compulsive disorder, somatoform disorders, dissociative disorders, impulse control disorders and autism |